Clinical Trials Arena

First hepatitis C self-test prequalified by WHO It remains to be seen if improving testing access through self-testing will lead to improved outcomes for those with hepatitis C. - https://lnkd.in/dJZVMKsY #hepatitisc #clinicaltrials

FDA clears Artelo Biosciences, Inc.’s FABP5 inhibitor trial Artelo’s CEO Gregory Gorgas said: “Receiving IND clearance validates our development efforts and underscores the potential impact of ART26.12 to improve patients’ lives. We look forward to sharing the initial clinical results with ART26.12 next year.” - https://lnkd.in/dMrCU4CG #clinicaltrials

IROS CRO, Prilenia and International Huntington Association team up for Huntington’s disease trial M42 Health deputy group chief operating officer Dr Dr. Fahed Al Marzooqi said: “The planned trial would represent a significant step towards shedding light on the ‘hidden disease’ and raise awareness at the national and global level.” Prilenia CEO Dr Dr. Michael Hayden MBChB , PhD said: “Pridopidine is a selective and potent sigma–1–receptor agonist with neuroprotective properties. In clinical studies, it demonstrated consistent treatment benefits across independent measures that are important to patients and families" IHA president Svein Olaf Olsen said: “This is the first time a clinical trial in Huntington’s Disease is planned to take place in the region; this collaboration with IROS and Prilenia will aid our understanding of the disease.” - https://lnkd.in/dWbYVM6K #clinicaltrials #clinicalresearch #cro #huntingdons #huntingdonsdisease

Rznomics Inc. to commence RNA editing therapy trial for retinitis pigmentosa Rznomics CEO Dr Seong-Wook Lee said: “The Clinical Trial Notification (CTN) marks an important milestone in addressing the high unmet medical need of autosomal dominant retinitis pigmentosa with rhodopsin mutation. Rznomics is committed to developing innovative RNA-based biopharmaceuticals for the treatment of various human rare and intractable diseases, and we look forward to the initiation of the clinical trial to evaluate the safety and efficacy profile of RZ-004 for providing a potential treatment option for patients suffering from the disease.” - https://lnkd.in/dMx6sTrc #clinicaltrials #rna #biopharma

Sirnaomics completes IND-enabling trials of siRNA therapy STP125G Sirnaomics founder, CEO, president, chairman of board, executive director Dr Patrick Lu said: “STP125G is the second drug candidate based on our GalAhead mxRNA technology that has shown excellent safety and potent efficacy results with the NHP models. Its long-lasting silencing activity against ApoC3 may provide better therapeutic benefit to patients suffering cardiovascular conditions, than those of antisense and other siRNA drugs. Those data readouts further validated STP125G as a novel siRNA therapeutic candidate for treatment of hypertriglyceridemia and other cardiovascular diseases, using our proprietary GalAhead-based delivery technology.” - https://lnkd.in/dYzedUFV #clinicaltrials #sirna #mxrna

Tampons containing arsenic and lead pose significant health risks A study by Shearston and colleagues has found several toxic metals in 30 different tampons across 14 separate brands. - https://lnkd.in/dDinc3dB #clinicaltrials #femtech #womenshealth #femalehealth

uniQure’s shares soar on positive data for Huntington’s gene therapy  uniQure’s chief medical officer Walid Abi-Saab said: “We believe this is the first clinical trial of any investigational medicine for Huntington’s disease to show evidence of a potential long-term clinical benefit and reduction of a key marker of neurodegeneration.  Moreover, given the one-time administration of AMT-130, we are in a unique position to continue accumulating longer-term patient outcomes from the Phase I/II studies to support the emerging therapeutic benefit.” - https://lnkd.in/dinsj_qG #clinicaltrials #huntingtons #huntingtonsdisease #genetherapy

Clinical trial success depends on strong outsourcing relationships Experts shared strategies for creating strong and cost-friendly outsourcing relationships that can propel clinical studies. Dr. Claudia Hesselmann, PhD, founder and CEO at ARENSIA Exploratory Medicine GmbH, Kevin Stephenson, Executive Director, Data Management at Karyopharm Therapeutics Inc. and David Sherris, Ph.D, Board of Director at SiVEC Biotechnologies. discussed the key drivers behind successful outsourcing strategies at our 13th Annual Clinical Trials in Oncology East Coast 2024 conference, being held 9 – 10 July in Burlington, Massachusetts. - https://lnkd.in/dtthjzi2 #clinicaltrials #clinicaltrialoutsourcing #oncology

Navigating Project Optimus in early oncology clinical trial design Experts james eamma, Executive Director, Therapeutic Strategy Lead, Oncology & Hematology at Worldwide Clinical Trials shared strategies for creating strong and cost-friendly outsourcing relationships that can propel clinical studies. - https://lnkd.in/dsiu4Yst #oncology #clinicaltrials #projectoptimus #clinicaltrialoutsourcing

Biotech investors remain cautious in a stabilising funding environment Investors continue to take a cautious approach while searching for novel candidates in an increasingly crowded oncology landscape. - https://lnkd.in/dBJuyjFj #clinicaltrials #biotech